Orchestra BioMed Holdings, Inc. (OBIO)
OBIO Stock Price Chart
Explore Orchestra BioMed Holdings, Inc. interactive price chart. Choose custom timeframes to analyze OBIO price movements and trends.
OBIO Company Profile
Discover essential business fundamentals and corporate details for Orchestra BioMed Holdings, Inc. (OBIO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
4 Aug 2020
Employees
70.00
Website
https://orchestrabiomed.comCEO
David Hochman
Description
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.
OBIO Financial Timeline
Browse a chronological timeline of Orchestra BioMed Holdings, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.35, while revenue estimate is $137.71k.
Earnings released on 12 May 2026
EPS came in at -$0.33 surpassing the estimated -$0.40 by +17.50%, while revenue for the quarter reached $110.00k , missing expectations by -88.03%.
Earnings released on 12 Mar 2026
EPS came in at $0.26 surpassing the estimated -$0.38 by +168.42%, while revenue for the quarter reached $30.92m , beating expectations by +3.22k%.
Earnings released on 10 Nov 2025
EPS came in at -$0.40 falling short of the estimated -$0.38 by -5.26%, while revenue for the quarter reached $861.00k , beating expectations by +16.13%.
Earnings released on 12 Aug 2025
EPS came in at -$0.50 surpassing the estimated -$0.51 by +1.96%, while revenue for the quarter reached $836.00k , beating expectations by +7.34%.
Earnings released on 2 Apr 2025
EPS came in at -$0.43 matching the estimated -$0.43, while revenue for the quarter reached $253.00k , missing expectations by -51.56%.
Earnings released on 26 Mar 2025
EPS came in at -$0.37 surpassing the estimated -$0.43 by +13.95%, while revenue for the quarter reached $253.00k .
Earnings released on 12 Nov 2024
EPS came in at -$0.41 surpassing the estimated -$0.44 by +6.82%, while revenue for the quarter reached $987.00k , beating expectations by +40.35%.
Earnings released on 12 Aug 2024
EPS came in at -$0.45 falling short of the estimated -$0.41 by -9.76%, while revenue for the quarter reached $778.00k , missing expectations by -8.47%.
Earnings released on 13 May 2024
EPS came in at -$0.38 surpassing the estimated -$0.40 by +5.00%, while revenue for the quarter reached $620.00k , missing expectations by -34.74%.
Earnings released on 27 Mar 2024
EPS came in at -$0.37 surpassing the estimated -$0.38 by +2.63%, while revenue for the quarter reached $262.00k , missing expectations by -73.66%.
Earnings released on 13 Nov 2023
EPS came in at -$0.38 surpassing the estimated -$0.39 by +2.56%, while revenue for the quarter reached $419.00k , missing expectations by -53.18%.
Earnings released on 10 Aug 2023
EPS came in at -$0.35 surpassing the estimated -$0.42 by +16.67%, while revenue for the quarter reached $915.00k , beating expectations by +29.60%.
Earnings released on 12 May 2023
EPS came in at -$0.40 falling short of the estimated -$0.28 by -42.86%, while revenue for the quarter reached $1.16m , beating expectations by +71.18%.
Earnings released on 25 Jan 2023
EPS came in at -$0.08 surpassing the estimated -$0.43 by +81.82%, while revenue for the quarter reached $1.10m , beating expectations by +55.35%.
Earnings released on 16 Dec 2022
EPS came in at -$0.05 , while revenue for the quarter reached $1.16m .
Earnings released on 30 Jun 2022
EPS came in at -$0.25 , while revenue for the quarter reached $401.00k .
Earnings released on 31 Mar 2022
EPS came in at -$0.18 , while revenue for the quarter reached $866.00k .
Earnings released on 31 Dec 2021
EPS came in at -$0.00 , while revenue for the quarter reached -$2.45m .
Earnings released on 30 Sept 2021
EPS came in at -$0.00 , while revenue for the quarter reached $1.33m .
OBIO Stock Performance
Access detailed OBIO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
